JPRN-jRCT1080220402未知3 期
A Multicentre, Randomised, Open-Label, Parallel-Group, Phase III Post-Marketing Clinical Study to Compare the Overall Survival Between Gefitinib and Docetaxel in Patients With Advanced or Metastatic (Stage IIIB/IV), or Recurrent Non-Small Cell Lung Cancer, Who Have Failed One or Two Chemotherapy Regimens
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 20 Years and above,
- •Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- You are histologically or cytologically confirmed to have recurrent or metastatic NSCLC
- •- You have been treated with chemotherapy including platinums for NSCLC.
排除标准
- •- You have received treatment for non-small lung cancer within 4 weeks before your participation in this study (except for specific therapies)
- •- You have or had any disease of acute lung injury, idiopathic pulmonary fibrosis, pulmonary pneumonia, or pneumoconiosis evident on the X-ray
- •- You have or had any disease of radiation pneumonia or drug-induced pneumonia, which requires treatment with corticosteroids
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative disorders such as chronic myeloid leukemia.MedDRA version: 6.1Level: PTClassification code 10028533EUCTR2004-001507-35-HUPharmion Corporation354
进行中（未招募）
1 期
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid ArthritisMedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-004339-21-PLsanofi-aventis Recherche & Développement200
进行中（未招募）
不适用
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisEUCTR2009-015556-15-CZBiogen Idec Limited76
进行中（未招募）
不适用
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisEUCTR2009-015556-15-LVBiogen Idec Limited76
进行中（未招募）
1 期
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative disorders such as chronic myeloid leukemia.MedDRA version: 6.1Level: PTClassification code 10028533EUCTR2004-001507-35-CZPharmion Corporation32